Clinical study on dapagliflozin combined with metformin for the treatment of type 2 diabetes mellitus
10.3760/cma.j.cn341190-20220124-00070
- VernacularTitle:达格列净联合二甲双胍治疗2型糖尿病的临床研究
- Author:
Jun MAO
1
;
Yonghong CAO
;
Huiru LIU
;
Liang CAO
;
Po HU
;
Ke ZHOU
;
Fan LI
;
Xiangyun MENG
Author Information
1. 安徽医科大学附属合肥医院 合肥市第二人民医院药学部，合肥 230026
- Keywords:
Diabetes mellitus,type 2;
Drug therapy,combination;
Hypoglycemic agents;
Metformin;
Dapagliflozin;
Blood Glucose;
Glycosylated hemoglobin;
Cholesterol;
Trigly
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(7):983-986
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effect of dapagliflozin combined with metformin on type 2 diabetes mellitus (T2DM).Methods:A total of 100 patients with T2DM who received treatment in The Second People's Hospital of Hefei from June 2019 to May 2021 were included in this study. They were randomly divided into a control group ( n = 50) and an experimental group ( n = 50). The control group was treated with metformin, and the experimental group was treated with dagglitazin combined with metformin. All patients were treated for 3 months. Blood glucose index, blood lipid level, and the incidence of adverse reactions were compared between the two groups. Results:After treatment, fasting blood glucose, 2-hour post-prandial blood glucose, and glycosylated hemoglobin in the experimental group were (5.56 ± 0.37) mmol/L, (8.32 ± 0.23) mmol/L, and (6.17 ± 0.26)% respectively, which were significantly lower than (6.96 ± 0.48) mmol/L, (9.58 ± 0.39) mmol/L, and (7.27 ± 0.26)% respectively in the control group ( t = 3.59, 6.92, 5.03, all P < 0.05). The total cholesterol and triglyceride in the experimental group were (3.58 ± 0.53) mmol/L and (1.25±0.26) mmol/L, respectively, which were significantly lower than (4.94 ± 0.58) mmol/L and (1.93 ± 0.18) mmol/L in the control group ( t = 3.16, 4.25, both P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusion:Dapagliflozin combined with metformin can effectively control blood glucose and blood lipid in T2DM patients without increasing adverse reactions.
